MOLECULAR PLAYERS OF LUNG CARCINOMA

Alok Singh*, Pooja Singh, Shraddha Prakash, Sridhar Mishra and Manish Kumar

ABSTRACT

Lung cancer is a leading root of cancer related death worldwide. It is increasing at a very fast rate in both men and women. Among all types of cancers, lung cancer is the commonest cancer type in the world. Due to poor prognosis of lung cancer patients, shows resistant to different therapies. Initiation, progression and treatment of the lung cancer can be achieved by the genome and transcriptome expression profiling of lung carcinoma. The identification of genetic mutations become possible by highthrouput genomic technologies (HTGT) and these technologies identifies that how these genetic mutation drives the progression of lung cancer and also revealed about the different targeted therapies like tyrosine kinase inhibitors that were proposed their action to combat changes at molecular level. These technologies introduce the novel biomarker for the detection of lung cancer at early stage. These biomarkers can be used as the diagnostic, prognostic and therapeutic purposes. In this review we summarized about different novel genetic mutations such as ALK, EGFR, MET, KRAS etc. in lung carcinoma.

Keywords: Lung Cancer, NSCLC, Inhibitor, Receptor tyrosine Kinase.